Abstract Details

Title Subjective Cognitive Decline: Self and Informant Comparisons

Topic Aging and Dementia

Presentation(s) P07 - (-)

Poster/Presentation
Number 145

Objective

Background BACKGROUND: There is conflicting data regarding whether subjective cognitive complaints simply reflect anxiety and other psychological factors or an early stage of AD.

Design/Methods DESIGN/METHODS: 447 cognitively normal members of the Arizona Apolipoprotein E (APOE) Cohort age 45-79 years (mean age 59.0 [7.4], education 15.6 [2.4], mini-mental status score 29.6 [.7]), 69% women, 40% were APOE e4 carriers) and their informants completed both the self and informant versions of the Multidimensional Assessment of Neurodegenerative Symptoms questionnaire (MANS), paired self and informant based questionnaires comprised of 87 questions that quantitatively assess behavioral changes that may have occurred over the preceding year.

Results RESULTS: 30.6% of APOE Cohort members and 26.2% of informants endorsed some level of decline on the MANS. APOE e4 carrier status (40% e4 carriers) and memory scores did not differ between self or informant-based subjective decliners and nondecliners, but both self and informant-based subjective decliners had slightly but statistically significantly higher depression, anxiety, and stress scores as well as lower executive measure scores than nondecliners. Followup duration for the cohort was 59.5(49.1) months over which time 16 members (mean age 68.3 [8.3]) subsequently met criteria for mild cognitive impairment (MCI). Those who developed MCI were older at entry than nonconverters (63.2[7.4] vs 58.9[7.3] years, p=.02), and 81.3% were APOE e4 carriers (p=.001). Self endorsement of decline preceded informant in 9, coincided in six, and trailed in one. Overall members self-endorsed decline earlier than their informants (59.6[32.1] vs 25.1[36.3] months before MCI; p=.008).

Conclusions CONCLUSIONS: Both self and informant based subjective decline correlated with greater psychological distress, and lower executive performance. Of those with incident MCI, self-endorsed decline generally preceded or coincided with informant reports.

Authors/Disclosures
Richard J. Caselli, MD, FAAN (Mayo Clinic) PRESENTER	The institution of Dr. Caselli has received research support from NIA. The institution of Dr. Caselli has received research support from State of Arizona.
	No disclosure on file
Francois H. Jacques, MD (Clinique Neuro-Outaouais)	No disclosure on file
Dona Locke, PhD (Mayo Clinic)	Dr. Locke has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Eric M. Reiman, MD (Banner Alzheimer's Institute)	Dr. Reiman has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Denali, Green Valley, Zinfandel, and Takeda. Dr. Reiman has received stock or an ownership interest from Alkahest, Alzheon, Aural Analytics, Denali, and United Neuroscience.. Dr. Reiman has received intellectual property interests from a discovery or technology relating to health care. Dr. Reiman has received personal compensation in the range of $500-$4,999 for serving as a Member, National Advisory Council on Aging (NACA) with NIA.

��ɫ��

��ɫ��